Emmanuel J. Favaloro

TL;DR: The current understanding of the pathogenesis, epidemiology, management and outcomes of patients with COVID-19 who develop venous or arterial thrombosis, and of those with preexistingThrombotic disease who develop CO VID-19 are reviewed.

TL;DR: Six categories of von Willebrand disease correlate with important clinical features and therapeutic requirements, and certain VWD types, especially type 1 and type 2A, encompass several pathophysiologic mechanisms that sometimes can be distinguished by appropriate laboratory studies.

TL;DR: It is explored whether increased D-dimer values — which are a frequent occurrence in patients with COVID-19 — may be associated with disease severity.

TL;DR: Since it has been shown that fluid-phase GMP-140 is antiinflammatory and downregulates CD18- dependent neutrophil adhesion and respiratory burst, its presence in plasma may be of major importance in preventing the inadvertent activation of neutrophils in the circulation.

TL;DR: The underlying pathogenesis and the interaction between multiple systems, resulting in propagation of immunothrombosis, are discussed and may lead to both an improved understanding of COVID-19 pathophysiology and identification of innovative and efficient therapeutic targets to reverse the otherwise unfavorable clinical outcome of many of these patients.